IMMUNITYBIO INC (IBRX) Stock News
NASDAQ:IBRX - Nasdaq - US45256X1037 - Common Stock
IBRX Latest News and Analysis
IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Explore this week's top-performing mid-cap stocks, including H&E Equipment Services' impressive 100.59% surge following an acquisition announcement by United Rentals. Discover why stocks like SEMrush and Blueprint Medicines also experienced significant gains, impacting investment portfolios positively.
ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details
On Wednesday, ImmunityBio, Inc. (NASDAQ:IBRX) released progress in its ongoing FDA discussions regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC). NMIBC BCG Unresponsive Papillary Disease: ImmunityBio is preparing to submit a supplemental Biologics License Application (sBLA) in 2025 for its treatment targeting Bacillus Calmette-Guérin (BCG) unresponsive NMIBC in the papillary indication. As published in
ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details
ImmunityBio advances NMIBC and NSCLC treatments with promising trial data and plans 2025 FDA submissions for innovative cancer therapies.
ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency
ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective
Investors Bag IBRX 6.2% Lower Than Its Secondary Stock Offering
Noteworthy Wednesday Option Activity: PIPR, CRK, IBRX
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
Biotech Billionaire Soon-Shiong Sued Over ImmunityBio Stock Move
Biotech billionaire Patrick Soon-Shiong was accused in a shareholder lawsuit of misleading ImmunityBio Inc. investors about the prospects of the company’s flagship cancer drug in order to enrich himself at their expense.
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
/PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated biotechnology company, and nCartes, Inc., a transformational cloud software platform...
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon
/PRNewswire/ -- USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their end-of-quarter results, the...
ImmunityBio Reports Third-Quarter 2024 Financial Results
